The establishment of eosinophil-based therapeutic strategies necessitates extensive prospective clinical trials in order to improve new therapeutic avenues, particularly in the era of the application of PDL1 immunotherapy in triple-negative breast cancer. This evidence concerns the gene CD274 and triple-negative breast carcinoma.